Differential miRNA expression in inherently high- and low-active inbred mice

Michelle Dawes¹, Kelli J. Kochan², Penny K. Riggs² & J. Timothy Lightfoot¹

¹ Department of Health and Kinesiology, Texas A&M University, College Station, Texas, USA
² Department of Animal Science, Texas A&M University, College Station, Texas, USA

Keywords
miRNA, physical activity, wheel running.

Abstract
Despite established health benefits of regular exercise, the majority of Americans do not meet the recommended levels of physical activity. While it is known that voluntary activity levels are largely heritable, the genetic mechanisms that regulate activity are not well understood. MicroRNAs (miRNAs) are small non-coding RNAs that inhibit transcription by binding to a target gene, inhibiting protein production. The purpose of this study was to investigate differential miRNA expression between inherently high- (C57L/J) and low- (C3H/HeJ) active inbred mice in soleus, extensor digitorum longus (EDL), and nucleus accumbens tissues. Expression was initially determined by miRNA microarray analysis, and selected miRNAs were validated by qRT-PCR. Expression of 13 miRNAs varied between strains in the nucleus accumbens, 20 in soleus, and eight in EDL, by microarray analysis. Two miRNAs were validated by qRT-PCR in the nucleus accumbens; miR-466 was downregulated (~4 fold; P < 0.0004), and miR-342-5p was upregulated (~115 fold; P < 0.0001) in high-active mice. MiR-466 was downregulated (~5 fold; P < 0.0001) in the soleus of high-active mice as well. Interestingly, miR-466 is one of several miRNA families with sequence located in intron 10 of Sfmbt2; miRNAs at this locus are thought to drive imprinting of this gene. "Pathways in cancer" and "TGFβ signaling" were the most significant pathways of putative target genes in both the soleus and nucleus accumbens. Our results are the first to consider differential miRNA expression between high- and low-active mice, and suggest that miRNAs may play a role in regulation of physical activity.

Introduction
There is a strong genetic component to the regulation of daily activity, with common environment accounting for only 3–6% of the variation (for review see Lightfoot 2011). Several potential candidate genes with regulatory roles in voluntary activity have been proposed, although none have shown a dramatic impact on phenotype (Lightfoot 2011). Thus, it is more likely that voluntary activity is regulated by many genes and/or many biological mechanisms, each with small effects. Our past work has led to speculation that intragenic, non-coding regions of the genome may function in regulation of the coding genes involved in innate physical activity levels (Lightfoot et al. 2010). Therefore, regulatory mechanisms such as microRNAs (miRNAs) that arise from these intragenic areas, are of interest in relation to complex phenotypes, and to date, have not been examined in relationship to voluntary physical activity levels.

MiRNAs are short sequences (~22 nucleotides) of non-coding RNA that regulate gene expression post-transcriptionally by binding to a target mRNA sequence. This
binding creates a physical block, preventing translation machinery from progressing down an miRNA strand, or by degrading the miRNA strand and preventing protein production altogether. Inside the nucleus, the “primary (pri-miRNA)” is transcribed from a sequence within intronic regions of DNA, which is cleaved and exported to cytoplasm as a single-loop structure referred to as the pre-miRNA (mir; Cullen 2004). Finally, the mature miRNA (miR) is single-stranded and produces a primary and secondary (denoted with *) sequence (Ambros et al. 2003). Strongly associated miRNA sequences are designated with suffixed letters, for example, miR-466b and miR-466c, which while quite similar, are derived from separate precursor sequences (Ambros et al. 2003).

MiRNAs have been shown to be responsive to exercise training, in both humans and mice, mostly in skeletal muscle (termed “myomirs”) and to a limited extent, blood plasma. Endurance training (Aoi et al. 2010; Baggish et al. 2011; Keller et al. 2011; By et al. 2013; Tonevitsky et al. 2013; Uhlemann et al. 2014) affects expression of different miRNAs than those identified in resistance exercise protocols (McCarthy and Esser 2007; Drummond et al. 2008; Davidsen et al. 2011; Sawada et al. 2013). Additionally, differential expression of some miRNAs occur immediately post-acute exercise bout, while other changes are not observed until weeks into training. Thus, alteration of miRNAs as a response to exercise stimulus is becoming well established. However, there has been much less work performed to suggest that miRNAs regulate the response to exercise. Davidsen et al. (Davidsen et al. 2011) evaluated miRNAs that differed between high and low responders to a 12 week resistance training protocol and showed that expression of miRNAs 378, 29a, 26a was diminished in individuals who were low responders, but did not change in high responders, while expression of miR-451 increased only in low responders. These authors also observed a correlation with abundance of miR-378 and muscle mass. Therefore, endogenous miRNA levels may contribute to individual variation in exercise response leading us to hypothesize that inherent miRNA expression may contribute to the regulation of physical activity levels as well.

Exercise capability through skeletal muscle function is only a part of the voluntary activity puzzle. The nucleus accumbens is considered the central reward center in the brain and was determined by previous work in our laboratory to be a potential site of activity regulation (Knab et al. 2009a, 2012; Ferguson et al. 2013). Dreyer (Dreyer 2010) also suggested that miRNAs played a role in drug addiction and brain neuropathology, often affecting the mesolimbic dopaminergic pathway. Knab et al. (Knab et al. 2009a) showed that decreased dopaminergic activity in the nucleus accumbens (which is a part of the mesolimbic pathway) is associated with increased activity levels in high-active mice, accompanied by lower D1 receptor and tyrosine hydroxylase expression levels. Some of these midbrain specific miRNAs involved with addiction are also involved with neurodegenerative ailments including Parkinson’s disease. Kim et al. (Kim et al. 2007) established that a miRNA expressed in brain dopaminergic neurons was diminished in Parkinson’s patients. Therefore, miRNAs may affect the endogenous central command drive to be active as well.

The purpose of this study was to determine whether systemic miRNA expression differences between inherently high-active and low-active mice can be observed in the brain (nucleus accumbens) and peripheral musculoskeletal (soleus and EDL) tissues. Knowledge of miRNA variability between high- and low-active mice will provide insight into the genetic regulatory mechanisms potentially causing differing levels of activity between these strains.

**Methods**

Our laboratory has repeatedly shown that C3H/HeJ inbred mice are low-active, with an average daily wheel running distance of 2.93 ± 0.57 km, and C57L/J inbred mice are high-active, running 7.95 ± 0.96 km on average daily (Lightfoot et al. 2004, 2008, 2010). Additionally, Knab, et al. (Knab et al. 2009b) showed voluntary wheel running within these strains is highly repeatable. In the current study, 12 (6♂, 6♀) C57L/J and 12 (6♂, 6♀) C3H/HeJ mice that were 8-weeks old (56 days; Jackson Labs, Bar Harbor, ME) were housed individually. Previous work from our laboratory has indicated that gene expression within strain can be altered by running-wheel exposure (Dawes et al. 2014), and thus mice in this study were housed with a “locked” running wheel (450 mm circumference, Ware Manufacturing, Phoenix, AZ) to provide the same enrichment environment without running activity and eliminating the potential for activity-induced changes in the miRNA profile. Food (Harland Tekland 8604 Rodent Diet, Madison, WI) and water were provided ad libitum. All mice were housed in the same room of the university vivarium with 12 h light/dark cycles and with temperature and humidity maintained at 19–21°C and 40–50%, respectively. After 1 week, the mice were anesthetized with 2–4% isoflurane and subsequently euthanized. The nucleus accumbens, soleus, and EDL muscle were harvested and flash frozen in liquid nitrogen, and then stored at −80°C for later analysis. Body composition was analyzed prior to sacrificing using the Lunar Piximus DEXA (dual-energy X-ray absorptiometry) instrument (Fitchberg, WI). All procedures were approved by the Texas A&M University Institutional Animal Care and Use Committee.
Total RNA was extracted from nucleus accumbens, soleus, and EDL using the Qiagen miRNeasy kit (Qiagen, Valencia, CA), with inclusion of the on-column DNA treatment, according to the manufacturer’s instructions. RNA was quantified on a Nanodrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA) and quality of RNA was assessed with an Agilent 2100 Bioanalyzer (Santa Clara, CA). Samples were chosen for arrays based on RNA integrity number (RIN) number and evaluation of the electropherogram provided by the Bioanalyzer, with samples having a RIN quality value of >7.5. Four male high-active and four male low-active samples from each tissue were evaluated by miRNA microarray (24 arrays total), assigned to an array at random. Agilent mouse miRNA microarrays (miRbase 17.0) – one color arrays with cyanine 3-Cp labeling – were used to detect global differential expression of miRNAs between high- and low-active animals from each of the three tissues. One hundred nanograms of total RNA in 2 μL was labeled and the entire mass of RNA was used in hybridization. Optional labeling and hybridization spike-ins were used, as suggested by the manufacturer, as well as the purification of labeled RNA on the Bio-Rad microbiospin columns (Hercules, CA). Additionally, glass array slides were immersed in Agilent’s washing and stabilization solution for protection against additional degradation by ozone. Arrays were immediately scanned with an Agilent G2505C Scanner at three micron resolution, using GEML file 035430_D_F_20121221 for feature extraction and the miRNA_107_Sep09 protocol. The extended range option was also used with the photo multiplier lower setting at 0.05.

Quality reports of individual arrays were evaluated; subsequently, some arrays were dismissed due to heterogeneity of probe expression across array. Data were analyzed via Agilent GeneSpring 12.5 GX software. Probes with expression less than background were considered “not detected” and were subsequently removed from the analysis in the nucleus accumbens and soleus files, and “edited” entity lists were manually imported into GeneSpring for further analysis. Statistical analyses were not affected by any “less than background” probes for the EDL. Retained arrays were separated by tissue and subsequently normalized by percentile shift and background noise of arrays was removed (“background” was considered as the bottom 20% signal intensity). A moderated t-test was used to identify differential miRNA expression between activity levels (as arrays were already separated by tissue) with the alpha value set a priori <0.05 and fold change (FC) ≥2.0. Benjamini-Hochberg false discovery rate (FDR) was also applied to account for multiple testing and the resulting statistical test was the “corrected P-value” which was defined as P < 0.05 (aka: q-value). All microarray information is MIAME (Minimum Information About a Microarray Experiment) compliant and has been deposited in NCBI’s Gene Expression Omnibus (Edgar et al. 2002), accessible through GEO Series accession number GSE56374 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56374).

Putative target genes of differentially expressed miRNAs were determined after GeneSpring analysis, incorporating predictions from TargetScan, PITA, PicTar, and/or microRNA.org, with miRNA to gene matching considered significant at P < 0.10. Putative target genes were then analyzed using DAVID (Database for Annotation, Visualization and Integrated Discovery v6.7; [da Huang et al. 2009] to determine predicted pathways and gene ontology (GO) terms, providing some insight into miRNA function. Putative target genes of soleus and EDL were also compared to differentially expressed proteins in soleus and EDL from a similar (age, living and harvesting conditions, no wheel, same number of each sex) cohort of C57L/J and C3H/HeJ mice from our laboratory, determined using two dimensional gel electrophoresis and subsequent mass spectrometry (Ferguson et al. 2014). MiRNAs warranting confirmation were selected by targets having similarity to differentially expressed proteins, and/or having a high fold change (FC) between strains, and/or GO terms with functional relevance to physical activity.

Validation of candidate miRNAs was carried out using Taqman® miRNA qRT-PCR assays (Life Technologies, Grand Island, NY). All miRNAs examined are listed in Table 1. A fivefold RNA dilution series was performed to determine optimal quantity of input RNA into the reverse transcription reaction, for each assay in each tissue. RNA from three samples including both sexes and strains were combined to make a heterogeneous pool of RNA for the dilution series beginning with 200 ng total RNA. TaqMan® microRNA reverse transcription kit (cat. No. 4366596) and the miRNA specific RT primer were used for reverse transcribing the miRNA. RNA (200 ng, as determined from the standard curve) was used into all RT reactions, contained in 15 μL and cycled under the following conditions: 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. The PCR product was diluted 1:2 in 25 ng/μL tRNA (Invitrogen, Carlsbad, CA) prior to qRT-PCR assays. Two μL cDNA was combined with 10.0 μL Taqman® universal PCR master mix - AmpErase® UNG (cat. No. 4324018), 1.0 μL miRNA specific primer, and 7.0 μL nuclease-free water in each qRT-PCR reaction. U6 snRNA and miR-99b-5p were used as endogenous reference miRNAs. MiR-99b-5p was selected for use as a reference as it was not differentially expressed on microarrays between activity levels (P = 0.94). The human analog of this assay, hsa-miR-99b-5p, was used (Table 1). Additionally, the miR-466p-3p assay was used in place of the miR-466b-3p assay, as it was the most homologous assay available at the time (Table 1).
miRNA Expression in High- and Low-active Mice

Results

No difference in percent body fat ($P < 0.107$; $14.2 \pm 1.8$ g C3H/HeJ; $12.8 \pm 2.0$ g C57L/J; mean $\pm$ SD) or weight ($P < 0.178$; $20 \pm 3.3$ g C3H/HeJ; $21.7 \pm 3.7$ g C57L/J; mean $\pm$ SD) was observed between the strains. The five microarrays removed due to poor signal quality included two low-active soleus, two high-active EDL, and one low-active nucleus accumbens. Hsa-miR-99b-5p proved an adequate control assay for all three tissues, not differing in expression between strains within tissues ($P = 0.69$ for nucleus accumbens, $P = 0.644$ for EDL, and $P = 0.225$ for soleus). Although U6 was shown to be similar between strains in the soleus ($P = 0.09$) and EDL ($P = 0.13$), it was different between strains in the nucleus accumbens ($P = 0.02$). Table 2 shows that in comparison to U6, miR-99b-5p had a smaller CoV overall, providing additional merit for use as a reference miRNA. Therefore, all expression results are presented using miR-99b-5p as the reference miRNA.

Thirteen miRNAs were differentially expressed between strains ($P < 0.05$) by microarray analysis in the nucleus accumbens (Table 3). Sequences for seven of these 13 miRNAs are located in the proximal end of chromosome 2, specifically in intron 10 of the Sfmbt2 gene, and all exhibited reduced expression in the high-active versus low-active mice. Of the 13 differentially expressed miRNAs, miR-342-5p ($P < 0.0001$; Fig. 1A) and miR-466d-3p ($P = 0.0004$; Fig. 1B) were chosen for validation by qRT-PCR. Additional analysis by sex indicated no difference between males and females for either miRNA ($P = 0.603$ and $P = 0.134$, respectively).

### Table 1. miRNA associations and qRT-PCR assay information

| miRNA family                  | Tissue miRNA evaluated in | miRNA validated by qPCR | Name of assay validated | Taqman assay ID |
|------------------------------|---------------------------|-------------------------|-------------------------|----------------|
| Small nuclear RNA            | All                       | U6                      | miRNA, U6 snRNA         | 001973         |
| mir-99                       | All                       | mir-99b-5p              | hsa-miR-99b-5p          | 000436         |
| mir-466                      | NA                        | mir-466d-3p             | mmu-miR-466d-3p         | 002535         |
| mir-342                      | Soleus                    | mir-342-5p              | mmu-miR-342-5p          | 002527         |
| mir-1960                     | Soleus                    | mir-1960                | mmu-miR-1960            | 121148 mat     |

| Tissue miRNA validated by qPCR | Name of assay validated | Taqman assay ID |
|-------------------------------|-------------------------|----------------|
| U6                            | miRNA, U6 snRNA         | 001973         |
| hsa-miR-99b-5p                |                         | 000436         |
| mmu-miR-466d-3p               |                         | 002535         |
| mmu-miR-342-5p                |                         | 002527         |
| mmu-miR-1960                  |                         | 121148 mat     |

| Variability of U6 and miR-99b as reference assays |
|---------------------------------------------------|
| Validation of U6 and miR-99b as reference assays  | *P-value* C of V | *P-value* C of V |
|---------------------------------------------------|
| Hsa-miR-99b                                      | 0.69 0.40       | 0.024* 0.71     |
| EDL                                              | 0.64 0.22       | 0.13 0.86       |
| Soleus                                           | 0.23 0.23       | 0.09 0.21       |

The *P*-value and coefficient of variation (CoV) for each tissue using miR-99b and U6 as endogenous reference miRNAs. Hsa-miR-99b-5p proved an adequate control assay for all three tissues, not differing in expression between strains within tissues. Although U6 was shown to be similar between strains in the soleus, it was different between strains in the nucleus accumbens. The CoV was greater, in general, when using U6 as the reference miRNA, providing additional support for the use of miR-99b as our endogenous reference miRNA.

*Significantly different expression, *P* < 0.05.

The BLAST search of miR-466b-3p and miR-466p-3p showed that the sequences have 100% identity matching. qRT-PCR cycles were run in triplicate on an Applied Biosystems 7900HT Fast Real-Time PCR System (Carlsbad, CA). Amplification data were analyzed with the Sequence Detection Software v. 2.2.2 (Applied Biosystems). Relative quantification was determined using the ΔΔCt method (Livak and Schmittgen 2001). The average ΔCt for all samples was used as the “reference” sample.

To determine whether U6 or miR-99b-5p were the most appropriate endogenous control to use, a modification to the ΔΔCt calculation was used to create a ratio (2^ΔΔCt with ΔΔCt = sample Ct – “reference”). Differential expression was then determined using a chi-square test for each miRNA assay in each tissue, as well as controls, with alpha values set a priori at 0.05 (JMP Pro10.0, SAS Institute, Cary, NC). Further analysis of the U6 and miR-99b-5p included calculation the coefficient of variation (CoV) for both potential endogenous controls within tissue. In all analyses, Ct values that were greater than 2.5 standard deviations away from the mean were considered outliers and eliminated from the dataset. If differential expression was observed, data were subsequently analyzed for sex differences.
| Systematic name | Regulation  | Fold change | Active sequence | Chr | Mirbase accession No | Position on chr | Strand | Stop position on chr |
|----------------|-------------|-------------|-----------------|-----|---------------------|-----------------|--------|----------------------|
| Nucleus Accumbens |             |             |                 |     |                     |                 |        |                      |
| mmu-miR-3095-3p | <0.001 Up   | 104         | AAAAACTCTCTCTCTGCA | Chr4 | MMAT0001491          | 58453959        | +      | 58453943             |
| mmu-miR-342-3p  | <0.001 Up   | 4           | ACGGGTGCGTCTTCTGT | Chr12| MMAT0000590          | 10986897        | −      | 109868912            |
| mmu-miR-342-5p  | <0.001 Up   | 257         | CTAAATCGATCGATGCTG | Chr6 | MMAT0004653          | 109868652       | −      | 109868669            |
| mmu-miR-375     | 0.03 Down   | 4           | TACACGCGAGGGCCAGC | Chr1 | MMAT000739           | 74947292        | +      | 74947278             |
| mmu-miR-376c    | <0.001 Up   | 3           | ACCTGAAATTCTCTATG | Chr2 | MMAT0003183          | 110960981       | −      | 110961000            |
| mmu-miR-466d-3p | <0.001 Down  | 54          | CTATGTTGCTCTTGTAT | Chr2 | MMAT0004931          | 10433650        | −      | 10433664             |
| mmu-miR-467a    | <0.01 Down  | 4           | TGATGTTGTTGTATGTA | Chr2 | MMAT0002108          | 10398019        | −      | 10398038             |
| mmu-miR-467b    | <0.01 Down  | 3           | CATATACGATCGACCT  | Chr2 | MMAT0005448          | 10402887        | −      | 10402903             |
| mmu-miR-467c    | <0.01 Down  | 87          | CACATATACGATCGACCACT | Chr2 | MMAT0004885          | 10395572        | −      | 10395589             |
| mmu-miR-5117    | <0.01 Up    | 191         | TAACCTTATGATCACTAAAC | Chr1 | MMAT0002625          | 162967492       | −      | 162967513            |
| mmu-miR-669f-3p | <0.01 Down  | 2           | ATACGTTGTTGTTATGTA | Chr2 | MMAT0005839          | 10388917        | −      | 10388934             |
| mmu-miR-669h    | <0.01 Down  | 194         | ACATATACGATCGCACAC | Chr2 | MMAT0009418          | 10390015        | −      | 10390032             |
| mmu-miR-669n    | <0.01 Down  | 3           | ACACACATCCACACACAAC | Chr2 | MMAT0009427          | 10430950        | −      | 10430967             |
| EDL             |             |             |                 |     |                     |                 |        |                      |
| mmu-miR-1957    | <0.01 Down  | 237         | GTCTATGCTCTACACT  | Chr4 | MMAT0009430          | 118802399       | −      | 118802415            |
| mmu-miR-1966    | <0.01 Down  | 80          | GACCTCTTCTGAGCC   | Chr8 | MMAT0009439          | 108139391       | −      | 108139405            |
| mmu-miR-1967    | <0.01 Down  | 68          | GCATCTCTCTCCAG    | Chr8 | MMAT0009440          | 126546597       | −      | 126546610            |
| mmu-miR-205     | <0.01 Down  | 326         | CAGACTCTCTGCTA    | Chr1 | MMAT0002238          | 195333684       | +      | 195333670            |
| mmu-miR-3091-5p | <0.01 Up    | 50          | GCGGCCCAACC       | Chr2 | MMAT0014903          | 17999262        | −      | 179992272            |
| mmu-miR-342-3p  | 0.02 Down   | 5           | ACCTGCTGCTTCTTCT  | Chr2 | MMAT000590           | 10986897        | −      | 10986912             |
| mmu-miR-5117    | <0.01 Up    | 120         | TAACCTTATGATCACTAAAC | Chr1 | MMAT0020625          | 162967492       | −      | 162967513            |
| mmu-miR-5118    | <0.01 Down  | 54          | ACCACATCCACACACACAC | Chr6 | MMAT0020626          | 55494889        | −      | 55494901             |
| Soleus          |             |             |                 |     |                     |                 |        |                      |
| mmu-miR-148a    | 0.02 Down   | 2           | AAAGTCTGCTGCTGAC  | Chr6 | MMAT000516           | 51219892        | +      | 51219874             |
| mmu-miR-184-3p  | <0.01 Down  | 52          | AGTCAAGCAGAGACCT  | Chr12| MMAT0014805          | 81492623        | +      | 81492608             |
| mmu-miR-192    | <0.01 Down  | 220         | TGACTCTCTCTACATCCA | Chr1 | MMAT0009390          | 162226082       | +      | 162226067            |
| mmu-miR-193  *  | <0.01 Down  | 80          | TACTCTGCTGCTGCA   | Chr11| MMAT0004544          | 79525486        | −      | 79525498             |
| mmu-miR-1960   | <0.001 Down | 101         | ACGCTCTCTTACAGCC  | Chr5 | MMAT0009433          | 30497297        | −      | 30497312             |
| mmu-miR-299    | <0.01 Down  | 22          | AACGGTCTTACGGTAC  | Chr12| MMAT0005457          | 110948982       | −      | 110948907            |
| mmu-miR-3 26   | <0.01 Down  | 42          | ACTGGAGGACGGGCACA | Chr7 | MMAT000559           | 106700843       | −      | 106700858            |
| mmu-miR-342-3p  | <0.01 Down  | 5           | ACCGCGTGGCTTCTG    | Chr2 | MMAT000590           | 10986897        | −      | 10986912             |
| mmu-miR-3 62-5p | <0.01 Down  | 31          | ATTCACACATGCTGCTCA | ChrX | MMAT000706           | 6819135         | +      | 6819119              |
| mmu-miR-376a    | <0.01 Down  | 79          | ACCTGCTGCTTCTTCTA | Chr2 | MMAT000740           | 110960239       | −      | 110962054            |
| mmu-miR-431     | <0.01 Down  | 42          | TGCTATGACGCGCTGCTC | Chr2 | MMAT001418           | 110828676       | −      | 110828689            |
| mmu-miR-466b-3p | <0.001 Down | 71          | TTACTATGCTGCTGCTGTA | Chr2 | MMAT004876           | 10395901        | −      | 10395917             |
| mmu-miR-467a   * | <0.001 Down | 169         | TGTAGGTTGCTGTTGATGTA | Chr2 | MMAT002108           | 10398019        | −      | 10398038             |
| mmu-miR-467b    | <0.001 Down | 227         | CATATACGATCGACCT  | Chr2 | MMAT0005448          | 10402887        | −      | 10402903             |

(Continued)
In the soleus, 20 miRNAs were found to be differentially expressed between strains by microarray. Four of the miRNA sequences differentially expressed in the soleus were also located in intron 10 of the Sfmbt2 gene, and were downregulated in the high-active animals, similar to the nucleus accumbens. MiR-466b-3p was amongst these four miRNAs (Table 3), and was determined to be differentially expressed between high- and low-active animals by qRT-PCR analysis ($P < 0.0001$; Fig. 1C), with no difference in expression between sexes ($P = 0.908$). In contrast to the microarray data, qRT-PCR analysis showed that miR-1960 only trended towards differential expression between strains ($P = 0.060$; Fig. 1D).

MiR-466d-3p (differentially expressed in the nucleus accumbens) and miR-466b-3p (differentially expressed in the soleus) are a part of the same family of miRNAs (Table 1). The mature miRNA sequences (~21mer) for these miRNAs are 100% identical. However, the stem-loop sequence (~80mer) is slightly different between these miRNAs (~90% identical according to BLAST comparison), which differentiates them. As the mature sequences of these miRNAs were assayed by qRT-PCR, we will simply refer to them as miR-466. There are multiple probes on the microarray with 16/C6 nucleotides for these miRNAs (the probe used to determine differential expression is listed under “active sequence” on Table 3), which provides distinction between these family members.

Finally, in the EDL, eight miRNAs were differentially expressed between strains as determined by microarray analysis (Table 3). However, no further validation of these miRNAs was conducted at this time, as quantities of RNA (200 ng determined by dilution series) were insufficient for additional qRT-PCR assays, beyond establishment of endogenous controls.

KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways of putative target genes generated through DAVID were observed for association with drive or capability to be physically active. Approximately 30.3% of putative target genes ($n = 130$) in the soleus were classified into 11 KEGG pathways ($P < 0.01$; Table 4), 27.7% of putative target genes ($n = 359$) in NA were classified into 39 pathways ($P < 0.01$; Table 5), and in the EDL, 31% of putative target genes ($n = 173$) were classified into 5 pathways ($P < 0.01$; Table 6). The most significant predicted pathways for both soleus and NA included “pathways in cancer” and “TGFβ signaling”. Additional pathways related to exercise capability that are noteworthy in the soleus are involved with vasculature development and muscle development (Table 4). In the NA, the most significant GO terms involved transcription regulation, as well as terms relating to metabolism and organ development (Table 5).
in the EDL were identified pertaining to neuron development and nerve impulse, as well as dopamine secretion (Table 6).

**Discussion**

It has been well established that a genetic component to voluntary physical activity levels exists and is independent of environment. However, voluntary physical activity is a complex phenotype, with evidence of regulation from both central and peripheral mechanisms (e.g. (Ferguson et al. 2014; Kelly et al. 2012)), making elucidation of the responsible mechanisms difficult. This project has shown that differential miRNA expression in the nucleus accumbens, soleus, and EDL is associated with differing inherent levels of physical activity. Specifically, miRNA microarray analysis identified 13 miRNAs in nucleus accumbens, eight in EDL, and 20 in soleus to be differentially expressed between high- and low-active strains of mice. Furthermore, miR-342-5p and miR-466 in the nucleus accumbens, and miR-466 in soleus were validated by qRT-PCR to be differentially expressed between the high- and low-active mice. These differential miRNA expression patterns may be contributors to regulation of physical activity.

Interpretation of the mechanisms regulating voluntary physical activity began with genomic analysis for QTL associated with physical activity in both human and animal populations, from which several candidate genes were proposed (Lightfoot 2011). However, as we have noted recently (Dawes et al. 2014), and as was eloquently observed by Flint, et al. (Flint et al. 2005), deriving genes/proteins of interest from QTL can be difficult and infrequently successful. Therefore, it was not surprising when a comparison of the genomic position of all differentially expressed miRNAs (Table 3) to previously identified activity QTL in these strains (Lightfoot et al. 2008, 2010; Leamy et al. 2011) indicated no overlap in location between the miRNA sequence and QTL. While correspondence of differentially expressed miRNA sequence to a QTL would be interesting, genome association studies utilize genomic DNA, in which sequence variability does not necessarily correspond to mRNA expression levels (Dawes et al. 2014). Recently, however, Ferguson and colleagues from our laboratory (Ferguson et al. 2014), have taken a “protein to gene” approach to uncovering regulation of voluntary activity by determining the proteome signature in peripheral tissue (EDL and soleus) of inherently high- and low-active mice, in attempts to better understand systemic variability between activity levels. The present miRNA study is an “intermediate” investigation of regulatory mechanisms, evaluating potential causative factors for the variable proteome observed by Ferguson, et al. (Ferguson et al. 2014).
miRNA Expression in High- and Low-active Mice

M. Dawes

In this study, we observed miR-466 in the nucleus accumbens and soleus to be differentially expressed between the strains. Specifically, miR-446d-3p in the nucleus accumbens and miR-466b-3p in the soleus, were downregulated in the high-active mice (Table 3; Fig. 1B and C). The mature sequences of these miRNAs are matching, although different qRT-PCR assays were utilized for validation (see Table 1). Both primary sequences are located in intron 10 of Sfmbt2 ("Scm-like with four mbt domains 2" gene) on the proximal end of mouse chromosome 2. Sfmbt2 has a similar genetic structure to the polycomb-group proteins, which are capable of chromatin remodeling and are known for silencing HOX genes (Lee et al. 2013). In mice and rats only, Sfmbt2 is imprinted in early embryos and extra-embryonic tissues, and contains sequences for many small RNAs (Kuzmin et al. 2008; Wang et al. 2011). It is suggested that it is the miRNA cluster that is causative of the imprinting at this locus and that most (~84%) of imprinted gene/miRNA arrangements are conserved in humans (Wang et al. 2011). This circumstance seems an uncommon genomic event; Wang, et al. (Wang et al. 2011) states that Sfmbt2 has been “caught in the act of becoming imprinted”. Therefore, as syntany is not conserved between human and mouse in this region, structure and regulation of this gene between human and mouse may also differ. Although these results bring to light limitations in translating miRNA results from mouse model to human, the magnitude of differential expression of these miRNAs between strains and their ability to imprint genes, gives merit to epigenetic modifications that may be key drivers in activity levels, especially in rodent models.

Several other miRNAs in the nucleus accumbens and soleus that we observed to be differentially expressed by microarray are also located in intron 10 of Sfmbt2 (see Table 3). MiR-669 is a part of this miR-297-669 cluster of miRNAs, shown by Druz, et al. (Druz et al. 2012) to be upregulated under nutrient depleted conditions in cell culture. Specifically, these authors showed that glucose deprivation caused oxidative stress, leading to histone acetylation of the miRNA promoter region, and activating expression of miR-466 h-5p and Sfmbt2. Therefore, considering expression of this miRNA cluster was diminished in our high-active animals compared to low active, we speculate that endogenous basal metabolic and ROS production differences may play a significant role in regulating voluntary activity levels. Thus, further studies should be conducted to validate similar functionality of miRNAs in this cluster, as well as expression level of Sfmbt2 between the high- and low-active strains.

Expression of miR-466 in the soleus was ~5 fold lower in high-active mice. Target gene analysis of miR-466 showed some similarity in gene families to Ferguson, et al.’s previous protein work (Ferguson et al. 2014). For example, phosphofructokinase, liver, type B (Pfkld – P = 0.04) was a target gene of miR-466b-3p, and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (Pfkfb1) protein was shown to be expressed higher in the low-active mice (Ferguson et al. 2014). The Pfklb1 gene produces a class of “bifunctional” enzymes that maintain levels of fructose-2,6-bisphosphatase (F-2,6-BP), which is required for glycolysis, and is specific to liver, heart, and skeletal muscle (Minchenko et al. 2003). The kinase portion of the enzyme synthesizes F-2,6-BP and the phosphatase degrades F-2,6-BP (Okar et al. 2001). Fructose-2,6-BP is the most powerful activator of the Pfk enzymes (Pilkis et al. 1995), which regulate glucose through glycolytic pathways. It is intriguing to note that

Table 4. KEGG pathways and GO terms for soleus putative target genes

| Pathways in cancer | 19 | 4.4 | 3.50E-02 |
|-------------------|----|-----|-----------|
| TGF-beta signaling pathway | 9 | 2.1 | 4.20E-02 |
| Cell cycle | 10 | 2.3 | 8.70E-02 |
| Renal cell carcinoma | 7 | 1.6 | 1.30E-01 |
| Ubiquitin mediated proteolysis | 8 | 1.9 | 5.60E-01 |
| Progesterone-mediated oocyte maturation | 6 | 1.4 | 5.80E-01 |
| Cytokine-cytokine receptor interaction | 11 | 2.6 | 5.70E-01 |
| Toll-like receptor signaling pathway | 6 | 1.4 | 6.80E-01 |
| Endocytosis | 9 | 2.1 | 7.00E-01 |
| Adherens junction | 5 | 1.2 | 6.90E-01 |
| Type II diabetes mellitus | 4 | 0.9 | 6.80E-01 |
| Angiogenesis | 8 | 1.9 | 4.60E-01 |
| Hemopoiesis | 12 | 2.8 | 4.60E-01 |
| Muscle tissue development | 8 | 1.9 | 4.80E-01 |
| Regulation of vascular smooth muscle cell differentiation | 6 | 1.4 | 4.10E-01 |
| Regulation of cellular response to stress | 1 | 0.1 | 2.10E-01 |
| Pathways in cancer | 11 | 2.6 | 5.70E-01 |
| TGF-beta signaling pathway | 6 | 1.4 | 6.80E-01 |
| Cell cycle | 10 | 2.3 | 8.70E-02 |
| Renal cell carcinoma | 7 | 1.6 | 1.30E-01 |
| Ubiquitin mediated proteolysis | 8 | 1.9 | 5.60E-01 |
| Progesterone-mediated oocyte maturation | 6 | 1.4 | 5.80E-01 |
| Cytokine-cytokine receptor interaction | 11 | 2.6 | 5.70E-01 |
| Toll-like receptor signaling pathway | 6 | 1.4 | 6.80E-01 |
| Endocytosis | 9 | 2.1 | 7.00E-01 |
| Adherens junction | 5 | 1.2 | 6.90E-01 |
| Type II diabetes mellitus | 4 | 0.9 | 6.80E-01 |
| Angiogenesis | 8 | 1.9 | 4.60E-01 |
| Hemopoiesis | 12 | 2.8 | 4.60E-01 |
| Muscle tissue development | 8 | 1.9 | 4.80E-01 |
| Regulation of vascular smooth muscle cell differentiation | 6 | 1.4 | 4.10E-01 |
| Regulation of cellular response to stress | 1 | 0.1 | 2.10E-01 |

Predicted pathways and gene ontology (GO) terms of differentially expressed miRNA target genes from soleus analyzed through DAVID. No. of genes and percent of genes; number of genes out of all putative target genes generated through Genespring software included in respective KEGG pathway or GO term category.
| KEGG pathways for putative target genes - nucleus accumbens | No. of genes included | % of genes included | P-value Benjamini adjusted |
|------------------------------------------------------------|-----------------------|---------------------|---------------------------|
| Pathways in cancer                                          | 48                    | 3.7                 | 3.50E-06                  |
| TGF-beta signaling pathway                                 | 21                    | 1.6                 | 1.90E-05                  |
| Endocytosis                                                 | 31                    | 2.4                 | 3.30E-04                  |
| Cell cycle                                                  | 21                    | 1.6                 | 4.40E-03                  |
| MAPK signaling pathway                                      | 31                    | 2.4                 | 3.00E-02                  |
| Hypertrophic cardiomyopathy (HCM)                          | 14                    | 1.1                 | 4.90E-02                  |
| Colorectal cancer                                           | 14                    | 1.1                 | 5.20E-02                  |
| Adipocytokine signaling pathway                             | 12                    | 0.9                 | 5.00E-02                  |
| Ubiquitin mediated proteolysis                              | 18                    | 1.4                 | 7.50E-02                  |
| Cytokine-cytokine receptor interaction                     | 27                    | 2.1                 | 7.30E-02                  |
| Cell adhesion molecules (CAMs)                              | 19                    | 1.5                 | 9.70E-02                  |
| Prostate cancer                                             | 13                    | 1                   | 1.20E-01                  |
| Renal cell carcinoma                                        | 11                    | 0.8                 | 1.30E-01                  |
| Focal adhesion                                              | 22                    | 1.7                 | 1.20E-01                  |
| Dilated cardiomyopathy                                      | 13                    | 1                   | 1.10E-01                  |
| Insulin signaling pathway                                   | 17                    | 1.3                 | 1.10E-01                  |
| Bladder cancer                                              | 8                     | 0.6                 | 1.20E-01                  |
| Hematopoietic cell lineage                                  | 12                    | 0.9                 | 1.20E-01                  |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC)      | 11                    | 0.8                 | 1.40E-01                  |
| Chronic myeloid leukemia                                    | 11                    | 0.8                 | 1.40E-01                  |
| Adherens junction                                           | 11                    | 0.8                 | 1.40E-01                  |
| Wnt signaling pathway                                       | 17                    | 1.3                 | 1.60E-01                  |
| Heparan sulfate biosynthesis                                | 6                     | 0.5                 | 1.60E-01                  |
| Acute myeloid leukemia                                      | 9                     | 0.7                 | 1.50E-01                  |
| Type II diabetes mellitus                                   | 8                     | 0.6                 | 1.90E-01                  |
| Melanoma                                                    | 10                    | 0.8                 | 1.80E-01                  |
| Thyroid cancer                                              | 6                     | 0.5                 | 1.80E-01                  |
| ECM-receptor interaction                                    | 11                    | 0.8                 | 1.80E-01                  |
| ErbB signaling pathway                                      | 11                    | 0.8                 | 2.20E-01                  |
| Gloma                                                       | 9                     | 0.7                 | 2.20E-01                  |
| mTOR signaling pathway                                      | 8                     | 0.6                 | 2.30E-01                  |
| Chemokine signaling pathway                                 | 18                    | 1.4                 | 2.70E-01                  |
| Axon guidance                                               | 14                    | 1.1                 | 2.80E-01                  |
| Long-term potentiation                                      | 9                     | 0.7                 | 2.90E-01                  |
| Pancreatic cancer                                           | 9                     | 0.7                 | 3.20E-01                  |
| SNARE interactions in vesicular transport                   | 6                     | 0.5                 | 3.30E-01                  |
| Gap junction                                                | 10                    | 0.8                 | 3.30E-01                  |
| NOD-like receptor signaling pathway                         | 8                     | 0.6                 | 3.30E-01                  |
| Melanogenesis                                               | 11                    | 0.8                 | 3.30E-01                  |

| GO terms for putative target genes - nucleus accumbens       | No. of genes | % of genes | P-value Benjamini adjusted |
|--------------------------------------------------------------|--------------|------------|---------------------------|
| Regulation of gene expression                                | 276          | 21.3       | 1.80E-12                  |
| Regulation of transcription                                 | 252          | 19.5       | 2.10E-11                  |
| Regulation of transcription, DNA-dependent                   | 170          | 13.1       | 1.40E-07                  |
| Positive regulation of gene expression                       | 72           | 5.6        | 2.90E-06                  |
| Positive regulation of transcription                         | 70           | 5.4        | 4.60E-06                  |
| Organ morphogenesis                                          | 80           | 6.2        | 1.60E-05                  |
| Embryonic organ development                                  | 40           | 3.1        | 1.90E-04                  |
| Tissue development                                           | 78           | 6          | 7.00E-04                  |
| Positive regulation of cell differentiation                  | 29           | 2.2        | 4.80E-03                  |
| Heart growth                                                 | 3            | 0.2        | 6.50E-01                  |

Predicted pathways and gene ontology (GO) terms of differentially expressed miRNA target genes from NA analyzed through DAVID. No. of genes and percent of genes; number of genes out of all putative target genes generated through Genespring software included in respective KEGG pathway or GO term category.
the regulatory pathway of two important metabolic enzymes were differentially expressed between high- and low-active mice in this miRNA study and the previous proteomic study (Ferguson et al. 2014), indicating that inherent differences in basal metabolism in skeletal muscle may have a regulatory role on voluntary physical activity levels.

In the nucleus accumbens, miR-342-5p was found to be upregulated (~115 fold) and miR-466 was downregulated (~4 fold) in the high-active mice. Target gene prediction found Tceanc (transcription elongation factor A (SII) N-terminal and central domain containing on the X chromosome) to be a target gene for both of these miRNAs (P = 0.03). While opposite trends in expression patterns exists between these two miRNAs, remembering that miRNAs bind to a target gene to elicit action, the greater relative fold change of miR-342-5p may be producing diminished protein expression of Tceanc, as well as other genes, in the high-active animals. Recent work by Ferguson, et al. (Ferguson et al. 2015).
2015) suggests that protein expression of transcription elongation factor A 3 (TceA3) is differentially expressed in the nucleus accumbens between high- and low-active mice. We find the gene function similarities noteworthy as indicators of the types of genes that are potentially systemic regulators of inherent activity in the nucleus accumbens, although more work needs to be carried out to investigate the interaction between these miRNA and protein levels.

Both soleus and nucleus accumbens putative target genes are included in KEGG pathways “pathways in cancer” and “Tgfβ signaling”. “Pathways in cancer” included genes such as Wnt9a, Shh, and zinc finger transcription factors, suggesting involvement in cell cycle. Tgfβ signaling (also including Tnf and Bmp5) is known to be involved in exercise, limiting skeletal muscle myogenesis (Coffey and Hawley 2007). Tnf and Shh were also identified in the muscle tissue development, angiogenesis, and vasculature development GO term categories. Consequently, miRNAs identified as differentially expressed regulate these pathways, leading to the basis for physiological differences in inherent voluntary wheel running between these strains. Keller, et al. (Keller et al. 2011) observed upregulation of genes associated with cardiovascular and embryonic tissue development in men that were high responders to a 6 week cycling program. These authors identified TGFβ as a top canonical pathway, as well as calcium through camodulin-dependent protein kinase (CamKII). CamKII is a putative target gene for miR-669f-3p, miR-342-3p, and miR-466d-3p in the nucleus accumbens. Similar to our findings, the aforementioned study determined that 22% of the miRNA genes target differentially expressed between their high and low responders fell into GO category of transcription regulation. Specifically, Keller, et al. (Keller et al. 2011) notes that SOX9 was involved in muscle adaption to aerobic training; SOX9 was a target for both miR-342-3p, and miR-466d-3p in this study as well. Wang, et al. (Wang et al. 2014) investigated differential miRNA expression between 2- and 4-cell developing C57BL/6 mouse embryos by miRNA microarray. Their results identified miR-466d-3p to be upregulated in 4-cell compared to 2-cell embryos. MiR-467b*, miR-669i, and miR-669 m-3p were also differentially expressed between developmental stages. These studies provide greater merit that our differentially expressed miRNAs may have regulatory roles on voluntary activity levels through developmental genes.

Finally, although no validation of miRNAs was performed in the EDL, the significance of the EDL is worth mentioning briefly. The EDL is a fast-twitch, oxidative muscle fiber muscle in the lower leg of rodents. While we presume that slow-twitch, oxidative muscle fibers are primarily engaged for long duration wheel running usually exhibited by the high-active animals, we do not disregard the potential involvement of fast-twitch fibers. Suwa, et al. (Suwa et al. 2003) observed rats that were inbred for fast-twitch fiber dominance actually had higher levels of voluntary wheel running than non-fast-twitch dominant controls. Our microarray results showed eight miRNAs to be differentially expressed between strains in the EDL; however, as previously stated, insufficient quantities of RNA were available for qRT-PCR assays beyond the endogenous controls and thus, validation of the EDL results awaits future studies.

In conclusion, this study presents the differential miRNA signature of inherently high- and low-active inbred mice. In the nucleus accumbens, miR-342-5p and miR-466 were validated as differentially expressed between strains by qRT-PCR, as was miR-466 in the soleus. Further experiments to determine the role of these miRNAs in activity regulation are needed including use of miRNA antagonists to down-regulate the differentially expressed miRNAs identified in this study, investigation of Sfmbt2 expression levels, and analysis of the interaction between miRNAs and selected target genes. Regardless, these results demonstrate the importance of miRNA gene expression and contribute additional insight into the regulatory mechanism of voluntary physical activity.

Acknowledgments

Additional thanks to David Ferguson, Emily Schmitt, Heather Vellers, Sheril Marek for their assistance and support with animals and assays, and to Robert Vaughn and Dr. Ivan Ivanov for assistance with GeneSpring and statistical measures.

Conflicts of Interest

None declared.

References

Ambros, V., B. Bartel, D. P. Bartel, C. B. Burge, J. C. Carrington, X. Chen, et al. 2003. A uniform system for microRNA annotation. RNA 9:277–279.

Aoi, W., Y. Naito, K. Mizushima, Y. Takanami, Y. Kawai, H. Ichikawa, et al. 2010. The microRNA miR-696 regulates PGC-1{alpha} in mouse skeletal muscle in response to physical activity. Am. J. Physiol. Endocrinol. Metab. 298: E799–E806.

Baggish, A. L., A. Hale, R. B. Weiner, G. D. Lewis, D. Systrom, F. Wang, et al. 2011. Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J. Physiol. 589:3983–3994.
Bye, A., H. Rosjo, S. T. Aspenes, G. Condorelli, T. Omland, and U. Wisloff. 2013. Circulating microRNAs and aerobic fitness—the HUNT-Study. PLoS ONE 8:e57496.

Coffey, V. G., and J. A. Hawley. 2007. The molecular bases of training adaptation. Sports Med. 37:737–763.

Cullen, B. R. 2004. Transcription and processing of human microRNA precursors. Mol. Cell. 16:861–865.

Davidse, P. K., I. J. Gallagher, J. W. Hartman, M. A. Davidsen, P. K., I. J. Gallagher, J. W. Hartman, M. A. Coffey, V. G., and J. A. Hawley. 2007. The molecular bases of differential regulation of skeletal muscle microRNA expression. J. Appl. Physiol. (1985) 110:309–317.

Dawes, M. J., T. Moore-Harrison, A. T. Hamilton, T. Ceaser, K. J. Kochan, P. K. Riggs, et al. 2014. Differential gene expression in high- and low-active inbred mice. Biomed. Res. Int. 2014:361048.

Dreyer, J. L. 2010. New insights into the roles of microRNAs in drug addiction and neuroplasticity. Genome Med. 2:92.

Druz, A., M. Betenbaugh, and J. Shiloach. 2012. Glucose depletion activates mmu-miR-466 h-5p expression through oxidative stress and inhibition of histone deacetylation. Nucleic Acids Res. 40:7291–7302.

Edgar, R., M. Domrachev, and A. E. Lash. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210.

Ferguson, D. P., E. E. Schmitt, and J. T. Lightfoot. 2013. Viro-morpholinos induced transient knockdown of physical activity related proteins. PLoS ONE 8:e61472.

Ferguson, D. P., L. J. Dangott, E. E. Schmitt, H. L. Vellers, and J. T. Lightfoot. 2014. Differential skeletal muscle proteome of high- and low-active mice. J. Appl. Physiol. 116:1057–1067.

Ferguson, D. P., L. J. Dangott, H. L. Vellers, E. E. Schmitt, and J. T. Lightfoot. 2015. Differential protein expression in the nucleus accumbens of high and low active mice. Behav. Brain Res. 291:283–288.

Flint, J., W. Valdar, S. Shifman, and R. Mott. 2005. Strategies for mapping and cloning quantitative trait genes in rodents. Nat. Rev. Genet. 6:271–286.

da Huang, W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:44–57.

Keller, P., N. B. Vollaard, T. Gustafsson, I. J. Gallagher, C. J. Sundberg, T. Rankinen, et al. 2011. A transcriptional map of the impact of endurance exercise training on skeletal muscle phenotype. J. Appl. Physiol. (1985) 110:46–59.

Kelly, S. A., D. L. Nehrenberg, K. Hua, T. J. Garland, and D. Pomp. 2012. Functional genomic architecture of predisposition to voluntary exercise in mice: expression QTL in the brain. Genetics 191:643–654.

Kim, J., K. Inoue, J. Ishii, W. B. Vanti, S. V. Voronov, E. Murchison, et al. 2007. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317:1220–1224.

Knab, A. M., R. S. Bowen, A. T. Hamilton, A. A. Gulledge, and J. T. Lightfoot. 2009a. Altered dopaminergic profiles: implications for the regulation of voluntary physical activity. Behav. Brain Res. 204:147–152.

Knab, A. M., R. S. Bowen, T. Moore-Harrison, A. T. Hamilton, M. J. Turner, and J. T. Lightfoot. 2009b. Repeatability of exercise behaviors in mice. Physiol. Behav. 98:433–440.

Knab, A. M., R. S. Bowen, A. T. Hamilton, and J. T. Lightfoot. 2012. Pharmacological manipulation of the dopaminergic system affects wheel-running activity in differentially active mice. J. Biol. Regul. Homeost. Agents 26:119–129.

Kuzmin, A., Z. Han, M. C. Goldberg, M. R. Mann, K. E. Latham, and S. Varmuza. 2008. The PcG gene Sfmbt2 is paternally expressed in extraembryonic tissues. Gene Expr. Patterns 8:107–116.

Leamy, L. J., D. Pomp, and J. T. Lightfoot. 2011. Epistatic interactions of genes influence within-individual variation of physical activity traits in mice. Genetica 139:813–821.

Lee, K., W. Na, J. H. Maeng, H. Wu, and B. G. Ju. 2013. Regulation of DU145 prostate cancer cell growth by Sclm-like with four mbt domains 2. J. Biosci. 38:105–112.

Lightfoot, J. T. 2011. Can you be born a couch potato? The genomic regulation of physical activity. Pp. 45–72 in L. S. Pescatello and S. M. Roth, eds. Exercise genomics. Humana Press, New York, NY.

Lightfoot, J. T., M. J. Turner, M. Daves, A. Vordermark, and S. R. Kleeberger. 2004. Genetic influence on daily wheel running activity level. Physiol. Genomics 19:270–276.

Lightfoot, J. T., M. J. Turner, D. Pomp, S. R. Kleeberger, and L. J. Leamy. 2008. Quantitative trait loci (QTL) for physical activity traits in mice. Physiol. Genomics 32:401–408.

Lightfoot, J. T., L. J. Leamy, D. Pomp, M. J. Turner, A. A. Fodor, A. M. Knab, et al. 2010. Strain screen and haplotype association mapping of wheel running in inbred mouse strains. J. Appl. Physiol. 109:623–634.

Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408.

McCarthy, J. J., and K. A. Esser. 2007. MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J. Appl. Physiol. (1985) 102:306–313.

Minchenko, O., I. Opentanova, and J. Caro. 2003. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett. 554:264–270.
Okar, D. A., A. Manzano, A. Navarro-Sabate, L. Riera, R. Bartrons, and A. J. Lange. 2001. PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem. Sci. 26:30–35.

Pilkis, S. J., T. H. Claus, I. J. Kurland, and A. J. Lange. 1995. 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase: a metabolic signaling enzyme. Annu. Rev. Biochem. 64:799–835.

Sawada, S., M. Kon, S. Wada, T. Ushida, K. Suzuki, and T. Akimoto. 2013. Profiling of circulating microRNAs after a bout of acute resistance exercise in humans. PLoS ONE 8: e70823.

Suwa, M., H. Nakano, Y. Higaki, T. Nakamura, S. Katsuta, and S. Kumagai. 2003. Increased wheel-running activity in the genetically skeletal muscle fast-twitch fiber-dominant rats. J. Appl. Physiol. (1985) 94:185–192.

Tonevitsky, A. G., D. V. Maltseva, A. Abbasi, T. R. Samatov, D. A. Sakharov, M. U. Shkurnikov, et al. 2013. Dynamically regulated miRNA-mRNA networks revealed by exercise. BMC Physiol. 13:9.

Uhlemann, M., S. Mobius-Winkler, S. Fikenzer, J. Adam, M. Redlich, S. Mohlenkamp, et al. 2014. Circulating microRNA-126 increases after different forms of endurance exercise in healthy adults. Eur. J. Prev. Cardiol. 21:484–491.

Wang, Q., J. Chow, J. Hong, A. F. Smith, C. Moreno, P. Seaby, et al. 2011. Recent acquisition of imprinting at the rodent Sfmbt2 locus correlates with insertion of a large block of miRNAs. BMC Genom. 12:204.

Wang, P., J. Cui, C. Zhao, L. Zhou, X. Guo, R. Shen, et al. 2014. Differential expression of microRNAs in 2-cell and 4-cell mouse embryos. Zygote 22:455–461.